Betaine Transport in Kidney and Liver: Use of Betaine in Liver Injury

Stephen A. Kempson      Komi Vovor-Dassu       Christopher Day

Department of Cellular and Integrative Physiology, Indiana University School of Medicine, Indianapolis, Indiana, USA

Key Words
Betaine/GABA transporter • Alcohol • Methyl donor • Hepatocyte • MDCK

Abstract
Betaine, also known as trimethylglycine, is an important human nutrient obtained from a variety of foods and also can be synthesized from choline. Betaine is much more abundant in kidney and liver compared to other mammalian organs. The principal role of betaine in the kidney is osmoprotection in cells of the medulla and it enters these cells via the betaine/γ-aminobutyric acid (GABA) transporter protein (BGT1), which is upregulated by hyperosmotic stress. This process has been studied in great detail. In liver, the main role of betaine is a methyl donor in the methionine cycle. However, recent studies showed that BGT1 is much more abundant in liver compared to kidney medulla. Despite this, the role of BGT1 in liver has received little attention. Entry of betaine into liver cells is a necessary first step for its action at the cellular level. Increased interest in betaine has developed because of a number of therapeutic uses. These include treatment of nonalcoholic fatty liver and hyperhomocysteinemia, a risk factor for atherosclerotic disease. Several important questions need to be addressed to better understand the potential of betaine as a therapeutic agent for other liver diseases, such as alcohol-induced injury. Heavy alcohol consumption is the most common cause for liver-related deaths and altered liver metabolism may contribute to hepatic, vascular, coronary, and cerebral diseases.
Introduction

Betaine is the trimethyl derivative of the amino acid glycine and is sometimes termed trimethylglycine. It is highly water-soluble and exists as the zwitterion (CH$_3$)$_3$N$^+$.CH$_2$COO$^-$. at neutral pH. Betaine filtered at the glomerulus is conserved by reabsorption along the nephron. The low fractional excretion of betaine was reported to be less than 6%, indicating that filtered betaine is nearly completely reabsorbed from the tubular lumen somewhere along the nephron [1]. One site is the proximal tubule, where betaine can be reabsorbed by cotransport with either Na$^+$ or H$^+$ across the luminal plasma membrane. The cotransporters were found to be independent of the presence of chloride ions and both were inhibited by L-proline [2]. Both the convoluted and straight segments are likely involved in the recovery of filtered betaine [1]. The specific sodium-dependent betaine transport system in the straight segment may be the sodium-dependent imino acid transporter (SIT1), a member of the solute carrier (SLC) 6A sodium/solute symporter family. SIT1 (SLC6A20) exhibits some properties of the long-sought IMINO system for proline [3, 4].

Betaine and kidney

Betaine in the kidney functions principally as an osmoprotectant. The always high (but changing) osmolarity in the interstitium of the inner medulla is essential for the normal process of water reabsorption and urine concentration [5]. The high osmolarity contributes to a 'hostile environment' [6] and an essential strategy for cellular survival is to accumulate osmotically active organic compounds. These balance the high extracellular osmolarity and preserve cell volume without interfering with cell function. This aids survival because cell shrinkage would facilitate apoptosis [7]. Betaine is an important osmolyte in the kidney and in other tissues such as brain. Betaine is present in blood plasma at about 0.1 mM and is derived from the diet and choline metabolism in the liver [8-11]. In contrast to reabsorption of filtered betaine by the proximal tubule in the cortex, cells in the kidney medulla accumulate betaine primarily from the blood supply and via the sodium and chloride coupled betaine/γ-aminobutyric acid GABA transport system (BGT1). This is an integral membrane protein localized in the basolateral plasma membrane and is a member of the SLC6A family (SLC6A12). BGT1 specific mRNA is predominantly present in the thick ascending limb of Henle's loop and in inner medullary collecting ducts and is osmosensitive [12]. Activation of BGT1 gene transcription in response to hyperosmotic stress suggests that the BGT1 transporter is primarily responsible for cellular betaine accumulation in these segments during osmotic stress. BGT1 expression is regulated by the transcription factor known as tonicity-responsive enhancer binding protein (TonEBP), also called nuclear factor of activated T-cells (NFAT5). This has been studied in great detail by Burg, Kwon and colleagues and has been reviewed elsewhere [13-18]. The renal BGT1 protein cotransports betaine (or GABA) with both Na$^+$ and Cl$^-$ ions [19, 20], and is upregulated more than 10-fold during hyperosmotic stress (500 mOsm) in cultured MDCK kidney cells [21, 22]. In our own unpublished studies, as expected, hypertonic stress for 24 hr increased the betaine content of MDCK cells from 287±81 in controls to 1276±114 nmol/mg protein (P<0.002, n=3). The 4-5 fold increase agrees closely with previously published data for these same cells [23].

Hyperosmotic upregulation of BGT1 is relatively slow, requiring almost 24 h for completion in cultured cells. In contrast, as shown recently, BGT1 is downregulated acutely by endocytosis triggered by extracellular adenosine, ATP or activators of protein kinase C [24, 25]. There is also recent evidence of acute upregulation of BGT1 transport in frog oocytes mediated by a specific kinase, possibly due to increased retention of BGT1 protein after insertion in the plasma membrane [7]. Although BGT1 has a higher affinity for GABA, its primary role in the kidney is betaine transport [19, 26], while GABA is likely the primary substrate for transport by brain BGT1 [13, 27].
Compared to the wealth of investigative studies on renal BGT1, there is scant information on the liver betaine transporter. A liver-specific isoform of BGT1 has been cloned [28] and BGT1 mRNA is expressed in liver tissue [13]. However, the role of liver BGT1 has received little attention, in part because it was thought to be absent from hepatocytes and only present in less abundant cell types, such as Kupffer and endothelial cells. [29-31]. This is surprising, given that TonEBP is also expressed in liver cells and, importantly, is transcriptionally active at normal osmolarity [13, 32]. More recent data from the Danbolt laboratory showed that liver BGT1 protein is much more abundant than kidney BGT1 in the mouse [33] and our own unpublished studies on hepatocytes from mouse liver confirmed the presence of BGT1 protein. In hepatocytes, isolated by collagenase perfusion [34], we observed that BGT1 was localized to the plasma membrane under iso-osmotic (280 mOsmol/kg) conditions (unpublished data, see Fig. 1), in marked contrast to renal medullary cells, where BGT1 remains intracellular until the onset of hyperosmotic stress [35]. However, the unexpected plasma membrane location in hepatocytes is consistent with the reported transcriptional activity of TonEBP at normal osmolarity (see above), suggesting that betaine transport is always 'switched on'. Further, we found that hepatocyte BGT1 was functional under iso-osmotic conditions as indicated by cell uptake of [14C]betaine in the presence of extracellular sodium and chloride ions. Na+/Cl−-dependent transport of betaine was sensitive to removal of extracellular Na+ and to inhibition by quinidine and nipecotic acid (unpublished data, see Fig. 2), similar to the activity of the renal BGT1 transporter [35]. Hepatocyte betaine transport also was partially inhibited by 100-fold excess of methylaminoisobutyric acid and carnitine (Fig. 2) raising the possibility that, at least under experimental conditions, some betaine uptake utilized the Na+-dependent system A amino acid transporter (ATA2) [36] and the ubiquitous Na+/L-carnitine cotransporter (OCTN2) [37]. The relative abundance of these transporters relative to BGT1 in liver remains unknown, but it appears there may be multiple pathways for hepatocytes to accumulate betaine. This reinforces the importance of betaine in liver and its role as a methyl donor. The betaine content of liver (and kidney)
greatly exceeds that of other organs, at least in the rat, and plasma betaine is conserved by very efficient renal reabsorption [11, 38].

Just as BGT1 is most abundant in liver compared to other tissues, so is betaine-homocysteine S-methyltransferase (BHMT) [33]. This enzyme converts homocysteine to methione by transferring a methyl group from betaine and in this reaction betaine is converted to dimethylglycine (DMG, Fig. 3). In an alternative pathway to form methionine (not shown), folate also can serve as a methyl donor and the methyl group is transferred to homocysteine by the enzyme methionine synthase (folate cycle). Chronic ethanol consumption has been shown to impair the activity of methionine synthase (see text). BHMT, betaine-homocysteine S-methyltransferase. DMG, dimethylglycine. SAM, S-adenosylmethionine. SAH, S-adenosylhomocysteine.

Abnormal methionine metabolism in liver is one result of alcohol abuse and appears to be a major factor in the pathogenesis of alcoholic liver disease. For example, the ethanol-induced decrease in SAM levels in liver leads to weakening of defense mechanisms, such as production of glutathione, the principal antioxidant [39], and other oxyradical scavengers [41]. In alcoholics and chronic ethanol-fed animals, hepatic SAM is depleted while SAH is increased, due in part to reduced activity of the methionine synthase. This leads to elevated levels of homocysteine in plasma. The liver SAM/SAH ratio indicates the capacity for methylation [38] and a decrease in the SAM/SAH ratio is indicative of disrupted
transmethylation reactions [42]. In this situation, betaine provides an alternative pathway (Fig. 3) to methylate homocysteine, form methionine and maintain a high SAM/SAH ratio [10, 43-45]. Consistent with increased use of betaine in this pathway, methionine synthase is depressed and plasma DMG (Fig. 3) is elevated during alcoholic liver disease in humans [46]. Another study also showed that ethanol feeding to rats impaired methionine synthase but proposed that the concomitant increase in the BHMT pathway utilizing betaine was sufficient to maintain SAM levels in the normal range. Further, dietary betaine supplementation increased SAM levels, especially in alcohol-fed animals [47]. More recent studies in rats [41, 48] confirmed that supplementation of dietary betaine was hepatoprotective in ethanol-fed animals. Hepatic SAM, cysteine and glutathione were reduced by ethanol feeding and all changes were reversed by subsequent betaine feeding. In a different context, it is interesting to note that homocysteine levels were elevated in liver cirrhosis which was attributed to downregulation of BHMT enzyme activity (Fig. 3), suggesting an association between deranged betaine metabolism and liver disease [49].

Our own studies in mice fed ethanol for four weeks, as part of a liquid diet, showed a 27% decrease in liver betaine content complemented by a 250% increase in content of the precursor choline, suggesting choline conversion to betaine was impaired. Phosphatidylcholine content was not significantly changed (unpublished data, see Fig. 4). A decrease in liver betaine after alcohol drinking also was reported by another group [50]. This raises some fundamental questions about betaine transport in liver. For example, is BGT1 the principal pathway for betaine uptake by hepatocytes, or are other transport systems (e.g. ATA2 or OCTN2) also important? What is the relative contribution of betaine transport compared to betaine synthesis in maintaining liver betaine content, and what is the effect of ethanol feeding on both processes? Is liver injury more severe when BGT1 is absent? Are tissue betaine levels during ethanol feeding restored by supplementation of dietary betaine, and if so, does this lead to reversal of liver injury? What happens to betaine transporters during this process? Hepatocytes in culture and the BGT1 knockout mouse, recently developed by Danbolt and colleagues [27], should be useful model systems for answering some of these important questions.

Conclusion

Heavy ethanol consumption interferes with myocardial metabolism and leads to increased risk of arrhythmias and sudden cardiac death [51-53], and the toxic action on brain and liver function has long been recognized. Alcohol use remains the most common cause for liver-related death and alcoholic liver disease is a major public health problem [54]. As many
as 2 million people in the US have alcohol-related liver disorders such as fatty liver, cirrhosis and cancer [55-57]. In humans, dietary betaine was found to improve liver function in fatty liver disease, including steatohepatitis [43, 48, 58, 59]. In animals and cultured cells, betaine had protective effects against liver injury, but the mechanism has not been determined [45, 60]. Clinical trials on the effectiveness of SAM for treating alcoholic liver disease have been inconclusive [10]. There has been a resurgence of interest in the therapeutic use of betaine for reducing alcohol-induced liver injury and a broad spectrum of cellular mechanisms have been proposed [59, 60-63]. Betaine is much less expensive than SAM, but few trials in humans have been reported and the data are limited [58, 64]. Exogenous betaine has already been used clinically to lower plasma homocysteine levels in humans since homocysteine is an independent risk factor for atherosclerotic disease [65, 66] and dementia [67]. It has been used extensively in animal and livestock nutrition [62]. Given the potential for safe and inexpensive improvement of human alcoholic liver disease, and possibly others such as liver cirrhosis, further studies of the role of betaine and its transport and metabolism at the cellular level are needed to better understand the intracellular mechanisms of betaine action in normal and diseased liver.

Conflict of Interests

No conflicts of interest to disclose.

Acknowledgements

The authors' work was supported in part by the American Heart Association Midwest Affiliate. We thank Professor NC Danbolt and Dr Y Zhou (University of Oslo, Norway) for many helpful discussions.

References


